Building the operating system for the global equine industry.

100,000+

Treatments delivered

60,000+

App downloads

144

Countries reached

16

Years of validation

I

Proven method, patented technology

100,000+ treatments over 16 years. European patent EP2549972B1. Atlas Horse device with 1,200+ units sold globally. This is not a hypothesis — it is a validated clinical method seeking scale.

II

Platform flywheel with compounding network effects

Ridesum (AI measurement) drives demand for treatment. Treatment generates data back to the platform. Certified partners expand the network. Each layer reinforces the others.

III

Massive, underserved market

The global equine industry exceeds $300 billion annually. Average horse owner spends six figures per year. Yet virtually all decisions are made without objective data. No incumbent platform exists.

Ridesum — B2C SaaS

AI-driven biomechanical analysis app for horse and rider. Subscription model at SEK 49/month. Currently live with 222 paying users across 144 countries.

Fascia Horse Clinics — B2B Platform

Franchise-style clinic network with certified therapists. Platform launching Q4 2026. Revenue from monthly license fees and treatment royalties.

Product Development

UX overhaul, AI feature expansion, merge of three existing systems into unified platform. Accelerated development of partner certification tools and data analytics dashboard.

User Acquisition

Scale Meta advertising from 1.5K to 50K+/month. Validate CAC at 50× current budget. Launch podcast and influencer partnerships for organic growth.

Clinic Platform & Expansion

Build and launch the B2B partner platform. First partner onboarding kits, certification materials, and training infrastructure. Nordic market entry.

Team & Operations

Key hires in product and sales. Legal costs for franchise agreements, IP protection, and regulatory compliance across target markets.

Working Capital

Buffer for unforeseen costs, currency fluctuations, and opportunistic investments. Ensures operational continuity during scaling phase.

Validate & Measure

• Scale Meta ads to 10× (4,500 kr/quarter) — validate CAC holds at scale
• Measure actual churn rate (most critical unknown)
• Target: 500+ paying Ridesum users by end of quarter
• Begin UX audit and product roadmap for platform merge

Scale & Content

• Scale Meta to 15,000 kr/month — validate CAC at 50× baseline
• Launch podcast series (Antonija collaboration)
• Community building: influencer partnerships, TikTok strategy
• Target: 4,000+ paying users, MRR approaching 500K

Platform Launch

• Fascia Horse Clinics B2B platform goes live
• First partner onboarding (certification kits, training)
• Merge Ridesum + treatment data into unified system
• Target: 4,100+ paying users, platform operational

Revenue Diversification

• First 15 paying clinic partners — license revenue begins (Q1)
• Treatment royalty revenue starts (Q2) as partners activate
• Scale Meta to 150,000 kr/month
• Target: 10,000+ users, 15+ partners, break-even achieved

Nordic Expansion

• Expand clinic network across Nordics (Norway, Denmark, Finland)
• 75+ certified partners by year-end
• ARR target: ~10M SEK
• Begin evaluation of US/Japan market entry

International Scale

• 30+ active clinic partners generating recurring revenue
• 9,500+ paying Ridesum users
• ARR target: 16M SEK
• Data platform: health trend reports, predictive analytics
• Evaluate Series A or strategic partnership for global expansion

Intellectual Property

European Patent EP2549972B1

Patented fascia treatment method for animals. Provides structural competitive moat against replication.

Axel Bohlin

CEO & Co-founder

Strategic lead. 16 years building the Fascia Innovation ecosystem. Drives franchise expansion, production scaling, and AI-driven knowledge platforms.

Klara Bohlin

COO, Ridesum

Operational lead for Ridesum. Manages user growth, community strategy, and content partnerships. Drove the 400% conversion increase.

Ivar Bohlin

Sales Director

Leads Atlas Horse machine sales globally. Manages B2B relationships and partner acquisition pipeline.

Camilla Ranje Nordin

Clinical Director

Head of treatment methodology and therapist certification. Ensures clinical quality across the partner network.

Kyra Kyrklund

Olympic medallist, dressage. Course partner and brand ambassador.

Lisen Bratt Fredricson

Elite rider. Course contributor and method advocate.

Rolf Göran Bengtsson

GCT champion. Indirect shareholder and proof-of-concept partner.

The model assumes 5% monthly churn, but this has not been validated. The difference between 2% and 10% churn is dramatic for the entire financial model.

Mitigant: Churn measurement is the #1 operational priority for Q2 2026. First reliable data expected within 60 days.

No formal partner agreements exist yet. The model assumes 15 paying partners in Q1 2027, ramping to 50/quarter by 2028.

Mitigant: Existing network of 1,200+ Atlas Horse device owners provides a warm pipeline. First formal agreements targeted for Q4 2026.

Current CAC of 9.50 kr is proven only at 1,500 kr/month spend. The model assumes 20% quarterly escalation, but actual scaling may be faster.

Mitigant: Phased scaling plan: 10× test in Q3, 50× in Q4. Each step validated before the next. Organic growth (25% of paid) provides buffer.

Revenue is currently concentrated in Sweden. International expansion introduces regulatory, cultural, and operational complexity.

Mitigant: 16 years of Swedish validation de-risks the method. Ridesum already has users in 144 countries. Nordic expansion is the natural first step.

The company relies heavily on the founding team's domain expertise and relationships.

Mitigant: Certification program systematizes knowledge transfer. Advisory board provides strategic depth. Platform reduces dependency on individual practitioners.

Merging three existing systems (Ridesum, treatment platform, clinic management) into one unified platform is technically complex.

Mitigant: 40% of proceeds allocated to product development. Phased integration approach reduces risk of single-point failure.